The in-vitro activity of MK-0826, a new oral carbapenem, was compared with that of imipenem by broth microdilution susceptibility tests against 545 bacterial isolates. MK-0826 had significantly greater activity against Enterobacteriaceae and poorer activity against Pseudomonas aeruginosa and many Gram-positive species. MK-0826 disc diffusion tests were also performed according to the NCCLS procedure and tentative interpretive criteria were determined for possible susceptible MIC breakpoints of 4.0 and 2.0 mg/L.
Introduction
Carbapenems are a class of -lactam antibiotics structurally characterized by having a trans-hydroxyethyl side chain in position 6 of the -lactam molecule, and they lack sulphur or oxygen in the bicyclic nucleus. They exert a broad range of antibacterial activity against both Gram-positive and Gram-negative bacteria, and are stable to most -lactamases. [1] [2] [3] [4] These features make them useful in the empirical treatment of many serious infections. 345 ) is a new oral carbapenem with broad spectrum antimicrobial activity. The present study was designed to: (i) define the in-vitro antibacterial activity of MK-0826, in comparison with imipenem, against a broad variety of common species of aerobic and facultatively anaerobic bacteria, and (ii) determine tentative interpretive criteria for disc diffusion tests using commercially prepared 10 g MK-0826 discs.
Materials and methods

Micro-organisms
A collection of 545 bacterial isolates representing 34 species was selected from our stock culture collection of clinical isolates. The individual species and the number of isolates of each species are listed in the 
Antimicrobial agents
The study drugs, MK-0826 and imipenem, were provided as standardized powder by Merck, Sharp and Dohme (Rahway, NJ, USA). For the disc diffusion studies, commercially prepared 10 g MK-0826 discs (BBL 508649) and 10 g imipenem discs (BBL 501629) were used.
Test procedures
Disc diffusion and broth microdilution susceptibility tests were those outlined by the National Committee for Clinical Laboratory Standards (NCCLS). 5, 6 When testing streptococci, the cation adjusted Mueller-Hinton broth was supplemented with 2-3% lysed horse blood to support growth and the agar contained 5% sheep blood.
Results and discussion
The Table summarizes the MICs of MK-0826 and imipenem for all 545 bacterial isolates tested. The activity of MK-0826 differed significantly from that of imipenem against different organism groups (Table) . Against members of the family Enterobacteriaceae, MK-0826 was considerably With the exception of Corynebacterium jeikeium, Gram-positive bacteria were inhibited by lower concentrations of imipenem than MK-0826. The differences were minimal for some streptococcal species, but were three-to-six-fold for different staphylococcal species. The Figure displays a scattergram comparing MK-0826 MICs and disc diffusion zone diameters. The zone diameter breakpoints were determined for possible MIC breakpoints of р2.0 or р4.0 mg/L for susceptible and у8.0 or у16 mg/L for resistant. The MIC breakpoint ultimately selected will depend on continuing pharmacokinetic studies and clinical data. With the р4.0 mg/L susceptible MIC breakpoint, the zone diameter breakpoints would be у16 mm for susceptible and р12 mm for resistant. With those breakpoints interpretive discrepancy rates were very low, i.e. no very major discrepancies, 0.2% major discrepancies, and 4.4% minor discrepancies. With a susceptible MIC breakpoint of р2.0 mg/L, the zone diameter breakpoints would be 3 mm larger, with no major discrepancies, 0.8% very major discrepancies and 2.9% minor discrepancies. The corresponding discrepancy rates for imipenem disc tests were 1.2%, 0 and 0.8%, respectively.
MK-0826 is an interesting carbapenem with excellent activity against most Enterobacteriaceae. Against other species, MK-0826 is active but imipenem is more potent. Disc diffusion susceptibility tests with 10 mg MK-0826 discs perform reliably: provisional interpretive criteria were selected for use during continuing clinical trials. Those provisional criteria will be reassessed once data are available from the clinical trials.
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